Gene therapy is at a pivotal moment. For eligible rare disease patients, the potential impact could be huge. So how can we support that potential to fruition and what will it mean if we do? In our season finale, host Adam Rutherford and guests take a peek into what a world with successful gene therapies could look like for patients, healthcare and society.

Featuring guests:
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Former Senior Project Manager, EURORDIS
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Paige Bischoff, Senior Vice President, Global Public Affairs,  Alliance for Regenerative Medicine
Paolo Morgese, EU Director, Market Access, Alliance for Regenerative Medicine
Reda Guiha, IDM Regional President, Rare Disease, Pfizer
Simone Boselli, Director, Public Affairs, EURORDIS
Tomislav Sokol, Member of European Parliament

As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them.

Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer 
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Senior Project Manager, EURORDIS
Katherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, Pfizer
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Suneet Varma, Global President, Rare Disease, Pfizer
Tomislav Sokol, Member of European Parliament



 

Gene therapy has come a long way to get where it is today but there is still much to learn and investigate. Host Adam Rutherford speaks to a line-up of experts about the vital role of clinical trials and the unique challenges facing gene therapy and rare disease patients.

Featuring guests:
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Professor John Rasko, Clinical Haematologist & Trial Investigator, University of Sydney
Simone Boselli, Director, Public Affairs, EURORDIS
Suneet Varma, Global President, Rare Disease, Pfizer

Gene therapy is a revolutionary field of science that has the potential to transform lives. It presents this big question; What if we could treat a disease at its root cause, rather than just the symptoms? On the first episode of Science Will Win, host Adam Rutherford takes us through the history, science, and significance of gene therapy.

Featuring guests:

Dirk Vander Mijnsbrugge, Vice President, Medical Affairs, Rare Diseases, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Laurence Woollard, Director, On The Pulse Consultancy
Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer

Science Will Win explores the fascinating science, policy, and humanity which is shaping the future of healthcare and transforming patients’ lives for the better. 

Hosted by Adam Rutherford, geneticist and Honorary Fellow at University College London, our first miniseries takes listeners on a journey behind the science of gene therapy; the next generation of medicines bringing new possibilities for patients living with rare genetic diseases. 

At a time when innovative science is achieving the seemingly impossible, we’ll look at gene therapy from every angle, speaking to scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy.